# The Medicines Company

Organization · id `cardio:org-the-medicines-company` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=The+Medicines+Company>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: The Medicines Company
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (`cardio:ct-nct01087723`)
- Sponsors: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) (`cardio:ct-nct01156571`)
- Sponsors: Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH (`cardio:ct-nct01651780`)
- Sponsors: GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation (`cardio:ct-nct01813435`)
- Sponsors: PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. (`cardio:ct-nct02171065`)
- Sponsors: Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (`cardio:ct-nct02597127`)
- Sponsors: MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial (`cardio:ct-nct02678923`)
- Sponsors: Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (`cardio:ct-nct03397121`)
- Sponsors: Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (`cardio:ct-nct03399370`)
- Sponsors: Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (`cardio:ct-nct03400800`)

## Provenance

Content hash: a5df72797c802c3b2dfa59abed9dd9ae78edec4bf140abd9a8e74343f6446c56
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
